OptimizeRx vs SOPHiA GENETICS
OptimizeRx reported revenue of $109 million in fiscal 2025, 1.4 times SOPHiA GENETICS's $77 million in fiscal 2025. OptimizeRx's revenue grew 18.8% in its latest year, and SOPHiA GENETICS's grew 18.6%. OptimizeRx had an operating margin of 10.7%, against -91.8% at SOPHiA GENETICS. Free cash flow was $19 million at OptimizeRx and −$36 million at SOPHiA GENETICS.
Side by side
| OptimizeRx | SOPHiA GENETICS | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $109M | $77M |
| Revenue growth | 18.8% | 18.6% |
| Revenue growth a year, last 5 years | 20.4% | 22.2% |
| Gross margin | 67.2% | 67.4% |
| Operating margin | 10.7% | −91.8% |
| Net margin | 4.7% | −102.2% |
| Free cash flow | $19M | −$36M |
| Free cash flow margin | 17.1% | −47.2% |
| Return on capital | 6.4% | −207.1% |
| Net debt to EBITDA | 0.2x | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 3.9% | 2.2% |
| Last close | $7.01 | $6.68 |
| P/E at the last close | 28.0× | — |
| Insider trades, last 12 months | sold $18,752 | bought $99,000, sold $4.2 million |
| Piotroski F-score | 8 of 9 | 2 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
OptimizeRxSOPHiA GENETICS
Operating margin
Percent of revenue
OptimizeRxSOPHiA GENETICS
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
OptimizeRxSOPHiA GENETICS
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the OptimizeRx and SOPHiA GENETICS pages.